ABCLAbCellera Biologics Inc.
$12.55+178% 1Y
$12.55
$2.7852 weeks$14.83
The financials
AbCellera Biologics Inc. by the numbers
AbCellera Biologics Inc. (ABCL) reported revenue of $4.0M in Q2 2026 (quarter ended Jun 30, 2026), down 76% from the same quarter a year earlier. That came with net loss of $55M. For the full year FY2025, revenue was $75M (+161% year on year) and net income −$146M. Its largest product in Q2 2026 was Research Fees at $3.9M, 96% of the disclosed total, well ahead of Licensing And Royalty at 3.7%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $4.0M | $17M | −76% |
| Operating income | −$63M | −$50M | n/a |
| Net income | −$55M | −$35M | n/a |
| Diluted EPS | −$0.18 | −$0.12 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Research Fees | $3.9M | 96% |
| Licensing And Royalty | $149K | 3.7% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $4.0M (-51%)
Research Fees grew -41% year on yearLicensing And Royalty -99% year on year
Segment Latestquarter on quarteryear on year
- Research Fees$3.9M$3.9Mquarter on quarter -52%year on year -41%-52%-41%
- Licensing And Royalty$149.0K$149.0Kquarter on quarter -22%year on year -99%-22%-99%